Orgenesis partners with Belgium"s RevaTis to develop stem cells for therapeutic use – Proactive Investors USA & Canada

Posted: April 9, 2020 at 3:49 am

The two firms plan to leverage Orgenesiss autologous Cell and Gene Therapy Biotech Platform to produce muscle-derived mesenchymal stem cells (mdMSC) as a source of exosomes

Inc () is teaming up with regenerative medicine and cell therapy firm RevaTis on a new joint venture to produce certain stem cells for therapeutic use, it said Wednesday.

The two firms plan to leverage Orgenesiss autologous Cell and Gene Therapy (CGT) Biotech Platform to develop novel therapies and advance clinical trials.

Under the agreement, RevaTis and Orgenesis will use the formers patented technique to obtain muscle-derived mesenchymal stem cells (mdMSC) as a source of exosomes and various other cellular products.

Orgenesis and RevaTis are hoping to build on RevaTiss early success in animals to develop therapies and advance human trials using Orgenesiss expertise and Point-of-Care platform, which include automated systems, 3D printing and bioreactor technologies.

RevaTiss technologies are highly differentiated and ideally suited for Orgenesiss CGT Biotech Platform, Orgenesis CEO Vered Caplan told shareholders.

We believe that this exclusive partnership with RevaTis further validates the significant value proposition of the Orgenesis vertically integrated business model, Caplan said in a statement Wednesday.

This model allows us to streamline the entire process of therapeutic development and delivery of cell therapies within the patient care setting through our Cell & Gene Biotech Platform.

RevaTis also has existing partnerships with research institutions in the US, the Middle East and India that will be highly complementary to Orgenesiss POCare Network, according to Caplan. We look forward to utilizing the Orgenesis Cell & Gene Biotech Platform with a goal to lower the costs and accelerate the timeline of bringing these innovative therapies through the clinic and potentially into commercialization.

RevaTis CEO Didier Serteyn said the firm was delighted to partner with Orgenesis on the new venture.

We selected Orgenesis as a result of their extensive experience in the field of autologous cell therapies, including technical, clinical and regulatory expertise, Serteyn said in a statement. We expect that this will be valuable as we aim to advance our platform through commercialization.

Germantown, Maryland-based Orgenesis is a vertically integrated biopharmaceutical company with expertise in developing advanced cell therapies and manufacturing.

Shares of Orgenesis jumped 5.8% on Wednesday to reach $4.40 by midday.

Contact Angela at [emailprotected]

Follow her on Twitter @AHarmantas

Read more:
Orgenesis partners with Belgium"s RevaTis to develop stem cells for therapeutic use - Proactive Investors USA & Canada

Related Posts

Comments are closed.

Archives